Could a diabetes drug help breast cancer survivors lose weight?
NCT ID NCT07257484
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether tirzepatide, a drug used for diabetes and weight loss, is practical and acceptable for postmenopausal women who have had hormone receptor-positive breast cancer and are obese. Thirty participants will take the drug weekly for 24 weeks, with monthly check-ins to monitor progress and safety. The goal is to see if it helps with weight loss and overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirzepatide
What this could lead to
If successful, this could show that tirzepatide is a practical option for weight management and better health in breast cancer survivors.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply widely. Side effects from tirzepatide are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••